2023-08-01 06:04:29 ET
- Esperion Therapeutics press release ( NASDAQ: ESPR ): Q2 GAAP EPS of -$0.46 beats by $0.15 .
- Revenue of $25.79M (+36.9% Y/Y) beats by $1.15M .
-
Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million
-
Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q
-
The Company still expects full year 2023 operating expenses to be approximately $225 million to $245 million, including $25 million in non-cash expenses related to stock compensation.
For further details see:
Esperion Therapeutics GAAP EPS of -$0.46 beats by $0.15, revenue of $25.79M beats by $1.15M